Currently, there are 38.93M common shares owned by the public and among those 32.75M shares have been available to trade.
The company’s stock has a 5-day price change of -11.14% and -53.35% over the past three months. SLDB shares are trading -18.25% year to date (YTD), with the 12-month market performance down to -59.43% lower. It has a 12-month low price of $3.03 and touched a high of $15.05 over the same period. SLDB has an average intraday trading volume of 384.68K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -15.05%, -30.91%, and -54.90% respectively.
Institutional ownership of Solid Biosciences Inc (NASDAQ: SLDB) shares accounts for 72.98% of the company’s 38.93M shares outstanding.
It has a market capitalization of $130.65M and a beta (3y monthly) value of 2.03. The earnings-per-share (ttm) stands at -$3.04. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.32% over the week and 8.49% over the month.
Analysts forecast that Solid Biosciences Inc (SLDB) will achieve an EPS of -0.72 for the current quarter, -0.75 for the next quarter and -2.84 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.91 while analysts give the company a high EPS estimate of -0.91. Comparatively, EPS for the current quarter was -1.0 a year ago. Earnings per share for the fiscal year are expected to increase by 40.08%, and -0.17% over the next financial year.
Looking at the support for the SLDB, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on January 08, 2025, with the firm’s price target at $16. Wedbush coverage for the Solid Biosciences Inc (SLDB) stock in a research note released on December 13, 2024 offered a Outperform rating with a price target of $16. JMP Securities was of a view on December 10, 2024 that the stock is Mkt Outperform, while JP Morgan gave the stock Overweight rating on July 15, 2024, issuing a price target of $10- $15. Leerink Partners on their part issued Outperform rating on June 24, 2024.
